This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About ImmunoGen Stock (NASDAQ:IMGN) Get ImmunoGen alerts:Sign Up Key Stats Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25VolumeN/AAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc. Read More Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMGN Stock News HeadlinesGridAI Technologies completes ImmunogenX ownership rescission transactionJanuary 7, 2026 | tipranks.comEntero Therapeutics Amends Rescission Agreement with ImmunogenXJuly 16, 2025 | tipranks.comEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.July 2 at 1:00 AM | Behind the Markets (Ad)BPDCN Market Set for Robust Growth Through 2032 Driven by Targeted Therapies and Rising Disease Awareness | DelveInsightApril 15, 2025 | theglobeandmail.comAbbVie's SWOT analysis: stock outlook strong despite humira lossFebruary 4, 2025 | msn.comAntibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchJanuary 22, 2025 | globenewswire.comPureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial OfficerNovember 5, 2024 | finance.yahoo.comSeaport Therapeutics Names Lauren White as Chief Financial OfficerNovember 5, 2024 | finance.yahoo.comSee More Headlines IMGN Stock Analysis - Frequently Asked Questions How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings data on Monday, July, 31st. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The firm's revenue was up 485.9% on a year-over-year basis. Read the conference call transcript. Does ImmunoGen have any subsidiaries? The following companies are subsidiaries of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings7/31/2023Today7/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income-$222.93 million Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableNo Data Beta1.18 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IMGN) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoGen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
